In a report issued on August 10, Keay Nakae from Chardan Capital reiterated a Buy rating on ProQR (NASDAQ: PRQR), with a price target of $9. The company’s shares closed on Friday at $7.35, close to its 52-week high of $7.75.
According to TipRanks.com, Nakae is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -19.3% and a 28.8% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arbutus Biopharma Corporation, Arcturus Therapeutics Ltd, and Arrowhead Research.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for ProQR with a $14.50 average price target, which is a 97.3% upside from current levels. In a report issued on August 9, H.C. Wainwright also maintained a Buy rating on the stock with a $20 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $7.75 and a one-year low of $2.75. Currently, ProQR has an average volume of 90.36K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ProQR Therapeutics NV is a biopharmaceutical company, which engages in the discovery and development of Ribonucleic Acid RNA based therapeutics for the treatment of genetic disorders. Its initial focus is on the development of a disease-modifying therapy for the treatment of cystic fibrosis.
